by Danny Sullivan – Longevity.Technology –
US biotech Tolerance Bio has launched with $17.2 million in seed financing to develop thymus-based therapies for immune-mediated diseases. The company focuses on preserving, regenerating and manipulating the thymus, an organ central to immune tolerance..
Philadelphia-based Tolerance Bio is developing an allogeneic cell therapy platform based on induced pluripotent stem cells (iPSCs) as well as pharmacological treatments aimed at immune diseases. By focusing on the thymus, the company addresses the core of immune regulation, seeking to preserve thymic function and restore it where it has declined or been lost.
